Voquezna (Vonoprazan) for Acid Reflux & LPR: Does It Work?

Short answer: yes, vonoprazan (brand name Voquezna) can meaningfully reduce reflux symptoms, and it does so faster and more consistently than a standard proton pump inhibitor (PPI). It’s a brand-new class of acid blocker, and the early evidence in laryngopharyngeal reflux (LPR) looks genuinely promising.

But I want to be honest with you up front, because I’ve spent more than eight years living with silent reflux and reading the research: vonoprazan is not a cure, the LPR studies so far are small, and it’s still acid suppression at its core. That last point matters more than most articles admit, and I’ll explain why below.

One more thing that affects a lot of my readers: as of early 2026, Voquezna is FDA-approved in the US but is not licensed for reflux in the UK. So before you get too excited, it’s worth understanding what it actually does, what the evidence shows, and where it fits.

Key Takeaways

• Vonoprazan (Voquezna) is a potassium-competitive acid blocker (P-CAB), a different class from PPIs like omeprazole and esomeprazole.
• It suppresses stomach acid faster, more potently, and more consistently than PPIs, including overnight.
• In erosive reflux, it healed the esophagus at least as well as (and by some measures better than) lansoprazole.
• In non-erosive reflux, it produced more heartburn-free days than placebo, though results across trials have been somewhat mixed.
• Early LPR trials suggest vonoprazan works at least as well as esomeprazole, with faster symptom improvement in the first weeks.
• It does not remove pepsin already deposited in your throat, and it doesn’t touch non-acid reflux, so diet and lifestyle still matter.
• It is not currently approved for reflux in the UK, and long-term safety data are still limited.

What Is Voquezna (Vonoprazan)?

Voquezna is the US brand name for vonoprazan, an oral tablet that belongs to a class of drugs called potassium-competitive acid blockers, or P-CABs. It was approved by the FDA in November 2023 for erosive esophagitis (erosive GERD), and again in July 2024 for heartburn linked to non-erosive GERD. It’s also used, combined with antibiotics, to eradicate H. pylori.

Vonoprazan itself isn’t brand new globally. It was launched in Japan back in 2015 and has been widely used across Asia for years. What’s new is its arrival in the Western reflux market as the first genuinely different acid blocker in over three decades.

P-CABs vs PPIs: the mechanism (this is the important part)

Your stomach makes acid using a “proton pump” (the H+/K+-ATPase enzyme) on the surface of parietal cells. Both PPIs and P-CABs shut this pump down, but they go about it very differently.

A PPI has to be activated in an acidic environment and then binds to the pump irreversibly. That sounds powerful, but it creates real-world quirks: PPIs work best taken 30–60 minutes before a meal, they only shut down pumps that are actively working at that moment, and they take a few days to reach full effect. They’re also processed by a liver enzyme called CYP2C19, which varies genetically from person to person, so two people can get quite different results from the same dose.

Vonoprazan blocks the same pump but competes with potassium to do it, reversibly and without needing an acidic trigger. In practice that means it starts working from the very first dose, it’s far less dependent on your CYP2C19 genetics, it can be taken with or without food, and it controls acid for longer, including through the night [Sugano, Therapeutic Advances in Gastroenterology, 2018]. That nocturnal point is a big deal for anyone with LPR, because a lot of the damage happens while you’re lying down asleep. If night-time is your problem, my guide on acid reflux at night covers this in more depth.

Does Vonoprazan Work for Acid Reflux (GERD)?

For classic GERD, the evidence is solid.

In the erosive esophagitis trials, vonoprazan 20 mg healed the esophagus in around 93% of patients by week 8, compared with about 85% for lansoprazole, a commonly used PPI. It was non-inferior for healing overall and actually did better in the tougher, more severe cases, and it held onto that healing better over six months [Laine et al., Gastroenterology, 2023].

For non-erosive reflux, the picture is good but slightly more nuanced. In a US trial, people on vonoprazan had roughly 45% heartburn-free days over four weeks versus about 28% on placebo, and the benefit started as early as day one and held up over a longer 20-week extension [Laine et al., Clinical Gastroenterology and Hepatology, 2024]. Worth noting: not every non-erosive trial has been equally positive, which is part of why some clinicians still reach for older, cheaper drugs first.

There’s also newer data suggesting vonoprazan specifically improves nocturnal reflux symptoms in non-erosive reflux, which again is relevant if your worst symptoms hit at night [Antunes et al., American Journal of Gastroenterology, 2025].

Does Vonoprazan Work for LPR and Silent Reflux?

This is the question I actually care about, and it’s where most drug articles go quiet, because LPR is chronically under-studied. The honest state of play: the LPR evidence is real, it’s encouraging, but it’s early and comes mostly from small trials.

The most useful study so far randomised 140 patients with LPR to either vonoprazan or esomeprazole. Both groups improved significantly on the standard reflux scores (RSI and RSS-12) at 4, 8, and 12 weeks. By 12 weeks the two drugs were broadly comparable, but vonoprazan produced faster symptom improvement in the first weeks of treatment [Wang et al., Journal of Voice, 2025]. If you’ve ever waited weeks for a PPI to “kick in” for throat symptoms, faster relief is a meaningful advantage.

That finding doesn’t stand alone. A related P-CAB, fexuprazan, was tested head-to-head against esomeprazole in LPR and performed comparably, which adds weight to the idea that this whole drug class has a role in throat reflux [Kim et al., European Archives of Oto-Rhino-Laryngology, 2024]. There are also case reports of vonoprazan helping stubborn reflux-related chronic cough that hadn’t responded to PPIs [Li et al., 2025], and chronic throat clearing and cough are classic LPR complaints. If those are your main symptoms, you might find my article on how to stop constant throat clearing from reflux useful alongside this.

Why I’m cautiously optimistic but not sold

Here’s the part I won’t skip, because it’s the whole reason Wipeout Reflux exists. Better acid suppression is genuinely helpful for LPR, but it doesn’t fix the underlying mechanism.

LPR damage is driven heavily by pepsin, an enzyme that piggybacks up with reflux and lodges in the delicate tissues of your throat. Pepsin can then be reactivated by any acid, including the acid in the food and drinks you consume, long after it’s arrived. A drug like vonoprazan lowers the acid coming up from your stomach, but it does nothing to remove pepsin that’s already sitting in your larynx. That’s exactly why so many people get partial relief from acid blockers and then plateau. I go deeper into this in my guide on how to neutralise pepsin in the throat.

On top of that, a decent chunk of LPR involves weakly-acidic, non-acid, or even gaseous reflux, and no acid blocker touches those. This is the reason PPI non-responders are so common in LPR, and if that’s you, it’s worth reading why your acid reflux medication might not be working. Switching to a stronger acid blocker can help, but it’s not the full answer, which is where a proper low-acid approach like the Wipeout Diet earns its place.

Is Vonoprazan Available in the UK?

This trips a lot of people up, so let me be clear. Voquezna is approved and available in the United States, and vonoprazan has been used for years in Japan and much of Asia and Latin America. But it is not currently licensed for reflux by the MHRA in the UK, where it has only appeared in clinical trials as an investigational drug.

So if you’re in the UK or Ireland like me, you can’t simply ask your GP for it as a reflux treatment right now. That may change, since the European rights are held by the company that markets it in the US, but there’s no UK reflux approval as I write this. It’s worth keeping an eye on, but in the meantime your realistic options remain PPIs, H2 blockers, alginates like Gaviscon Advance, and diet and lifestyle change.

Side Effects and Safety Considerations

Vonoprazan is generally well tolerated in the trials, but “new” is the operative word, and long-term safety data are still thinner than they are for PPIs that have been around for decades.

The most commonly reported side effects include gastrointestinal upset such as diarrhoea, urinary tract infections, and cold-like symptoms. It shouldn’t be taken with the HIV medication rilpivirine, and because it’s such a potent, sustained acid blocker, it raises the same theoretical long-term questions that surround any strong acid suppressant, including elevated gastrin levels. There was also a manufacturing-related nitrosamine impurity issue that delayed its original US approval, which the company subsequently resolved.

None of this is a reason to panic, but it is a reason to treat vonoprazan as a prescription drug to be discussed with a doctor, not a supplement to experiment with. And whatever acid blocker you’re on, coming off it needs care, because stopping abruptly can trigger rebound acid. I’ve written about that specifically in getting off PPIs and acid rebound, and the same principle applies here.

Where Vonoprazan Actually Fits

If I put my “eight years of LPR” hat on, here’s how I’d frame it. Vonoprazan looks like a better tool than a standard PPI for the acid part of the problem, especially for faster relief and better night-time control. That makes it a reasonable option to discuss with a specialist if you’ve had a genuine, well-managed PPI trial and it hasn’t worked, and if you can actually access it.

But it’s a better acid blocker, not a different strategy. It won’t remove pepsin, it won’t address non-acid reflux, and it won’t undo the dietary and lifestyle drivers behind your symptoms. The people I’ve seen do best treat any acid-suppressing drug as one leg of a stool, alongside a low-acid diet, sensible timing of meals, and pepsin-aware habits. If you want to understand the bigger picture first, start with my complete guide to LPR.

Frequently Asked Questions

Is vonoprazan better than omeprazole for reflux?

For raw acid control, yes, vonoprazan is faster and more potent, and it doesn’t depend on your CYP2C19 genetics the way omeprazole and esomeprazole do. Whether that translates into better real-world results for you depends on how acid-driven your reflux actually is. For straightforward heartburn and erosive disease the advantage is clearest; for LPR it helps, but it isn’t a magic bullet.

Can vonoprazan cure LPR or silent reflux?

No. It can significantly reduce symptoms by controlling acid, and the early trials show that, but it doesn’t cure the condition. It doesn’t remove pepsin from throat tissue or address non-acid reflux, which is why diet and lifestyle remain essential.

How fast does vonoprazan work?

Faster than a PPI. Because it doesn’t need to be activated by acid and blocks the pump from the first dose, symptom improvement can begin on day one, and the LPR data specifically showed quicker early improvement than esomeprazole.

Can I get Voquezna in the UK?

Not for reflux, at least not yet. It’s FDA-approved in the US but is not currently MHRA-licensed for reflux in the UK. Talk to your doctor about the options that are actually available to you here.

Do I still need to follow a reflux diet if I take vonoprazan?

Absolutely. Better acid suppression reduces the acid coming up, but dietary acid can still reactivate pepsin already sitting in your throat, and food and lifestyle drive a large share of reflux. Medication and diet work best together.

The Bottom Line

Vonoprazan (Voquezna) is the most interesting thing to happen to reflux medication in a long time. It’s a genuinely different class of acid blocker that works faster, hits harder, and controls acid more consistently through the night than the PPIs most of us have relied on for years. The GERD evidence is strong, and the early LPR trials suggest it holds its own against esomeprazole with quicker symptom relief. For anyone who’s had a proper PPI trial fail on the acid front, that’s real, encouraging news.

But I’d gently pump the brakes. It’s still acid suppression, and LPR has never been purely an acid problem. Pepsin lodged in your throat, non-acid reflux, meal timing, and the foods you eat all sit outside what any acid blocker can reach. That’s the gap that catches so many people out, and it’s the reason a better pill on its own so often leads to partial relief and a frustrating plateau. It’s also not yet available for reflux in the UK, so for many of us this is one to watch rather than one to chase.

If you take one thing from this, let it be that the medication is only ever half the strategy. The other half is what goes in your mouth and how you live. If you’re ready to build that side properly, the Wipeout Diet is my in-depth, step-by-step plan for calming reflux and LPR at the source, and it’s the more complete resource for understanding the whole approach. If you just want a quick, practical starting point, grab the Wipeout Food Reference Guide, an essential reference covering the foods and drinks that are safe for acid reflux and LPR along with their pH values. Between the right medication conversation with your doctor and the right approach at the dinner table, you’ve got a genuinely powerful combination.

Research and References

• Sugano, Therapeutic Advances in Gastroenterology, 2018 — A review of vonoprazan showing faster onset, longer duration, more potent acid suppression, and independence from CYP2C19 compared with PPIs, including higher daytime and night-time intragastric pH from the first day.
• Laine et al., Gastroenterology, 2023 — Randomised trial in over 1,000 patients showing vonoprazan was non-inferior to lansoprazole for healing erosive esophagitis and superior for maintenance of healing over six months.
• Laine et al., Clinical Gastroenterology and Hepatology, 2024 — US randomised trial in non-erosive reflux disease showing more heartburn-free days with vonoprazan than placebo, with benefit beginning as early as the first day of therapy.
• Antunes et al., American Journal of Gastroenterology, 2025 — Analysis showing vonoprazan improved nocturnal reflux symptoms in patients with non-erosive reflux disease.
• Wang et al., Journal of Voice, 2025 — Randomised trial of 140 LPR patients comparing vonoprazan with esomeprazole; both improved reflux scores, with vonoprazan showing faster early symptom improvement and comparable results by 12 weeks.
• Kim et al., European Archives of Oto-Rhino-Laryngology, 2024 — Randomised trial of the P-CAB fexuprazan versus esomeprazole in LPR, supporting a role for potassium-competitive acid blockers in throat reflux.
• Li et al., 2025 — Case series describing successful treatment of refractory reflux-induced chronic cough with vonoprazan after PPI failure.